Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma

Gynecologic Oncology

Volumn 106, Issue 2, 2007, Pages 311-317

  Lee, Sunyoung ^a,c   Garner, Elizabeth I O ^a,b   Welch, William R ^a   Berkowitz, Ross S ^a,b   Mok, Samuel C ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c CHA University   (South Korea)

Author keywords

HIF 1 ; Ovarian carcinoma; VHL

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; VON HIPPEL LINDAU PROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOLOCALIZATION; MAJOR CLINICAL STUDY; MICRODISSECTION; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; CARCINOMA, ENDOMETRIOID; CELL HYPOXIA; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 34447619912     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.03.041     Document Type: Article

References (30)

1. SEER Cancer Statistics Review 1975-2003 [http://seer.cancer.gov/csr/1975_2003/results_single/sect_01_table.01.pdf].
2. Barber H.R. Ovarian cancer: Part II. CA Cancer J Clin 30 (1980) 2-15
3. Ohkawa K., Amasaki H., Terashima Y., Aizawa S., and Ishikawa E. Clear cell carcinoma of the ovary: light and electron microscopic studies. Cancer 40 (1977) 3019-3029
4. Crozier M.A., Copeland L.J., Silva E.G., Gershenson D.M., and Stringer C.A. Clear cell carcinoma of the ovary: a study of 59 cases. Gynecol Oncol 35 (1989) 199-203
5. Behbakht K., Randall T.C., Benjamin I., Morgan M.A., King S., and Rubin S.C. Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol 70 (1998) 255-258
6. Recio F.O., Piver M.S., Hempling R.E., and Driscoll D.L. Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy. Cancer 78 (1996) 2157-2163
7. Goff B.A., Sainz de la Cuesta R., Muntz H.G., Fleischhacker D., Ek M., Rice L.W., et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 60 (1996) 412-417
8. Polverino G., Parazzini F., Stellato G., Scarfone G., Cipriani S., and Bolis G. Survival and prognostic factors of women with advanced ovarian cancer and complete response after a carboplatin-paclitaxel chemotherapy. Gynecol Oncol 99 (2005) 343-347
9. Hockel M., Vorndran B., Schlenger K., Baussmann E., and Knapstein P.G. Tumor oxygenation: a new predictive parameter in locally advanced cancer of the uterine cervix. Gynecol Oncol 51 (1993) 141-149
10. Hockel M., Schlenger K., Mitze M., Schaffer U., and Vaupel P. Hypoxia and radiation response in human tumors. Semin Radiat Oncol 6 (1996) 3-9
11. Sutherland R.M., Ausserer W.A., Murphy B.J., and Laderoute K.R. Tumor hypoxia and heterogeneity: challenges and opportunities for the future. Semin Radiat Oncol 6 (1996) 59-70
12. Carmeliet P., Dor Y., Herbert J.M., Fukumura D., Brusselmans K., Dewerchin M., et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394 (1998) 485-490
13. Wang G.L., Jiang B.H., Rue E.A., and Semenza G.L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci 92 (1995) 5510-5514
14. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux F.E.C., Cockman M.E., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
15. 2-regulated prolyl hydroxylation. Science 292 (2001) 468-472
16. Wenger R.H., Stiehl D.P., and Camenisch G. Integration of oxygen signaling at the consensus HRE. Sci STKE (2005) re12
17. Wenger R.H. Mitochondria: oxygen sinks rather than sensors?. Med Hypotheses 66 (2006) 380-383
18. Zhong H., De Marzo A.M., Laughner E., Lim M., Hilton D.A., Zagzag D., et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59 (1999) 5830-5835
19. Bos R., van der Groep P., Greijer A.E., Shvarts A., Meijer S., Pinedo H.M., et al. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97 (2003) 1573-1581
20. Kuwai T., Kitadai Y., Tanaka S., Onogawa S., Matsutani N., Kaio E., et al. Expression of hypoxia-inducible factor-1alpha is associated with tumor vascularization in human colorectal carcinoma. Int J Cancer 105 (2003) 176-181
21. Kurn N., Chen P., Heath J.D., Kopf-Sill A., Stephens K.M., and Wang S. Novel isothermal, linear nucleic acid amplification systems for highly multiplexed applications. Clin Chem 51 (2005) 1973-1981
22. Foster K., Prowse A., van den Berg Am Fleming S., Hulsbeek M.M., Crossey P.A., Richards F.M., et al. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet 3 (1994) 2169-2173
23. Gnarra J.R., Tory K., Weng Y., Schmidt L., Wei M.H., Li H., et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7 (1994) 85-90
24. Shannon A.M., Bouchier-Hayes D.J., Condron C.M., and Toomey D. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev 29 (2003) 297-307
25. Kallio P.J., Okamoto K., O'Brien S., Carrero P., Makino Y., Tanaka H., et al. Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1alpha. EMBO J 17 (1998) 6573-6586
26. Chun Y.S., Choi E., Kim T.Y., Kim M.S., and Park J.W. A dominant-negative isoform lacking exons 11 and 12 of the human hypoxia-inducible factor-1alpha gene. Biochem J 362 (2002) 71-79
27. Koukourakis M.I., Giatromanolaki A., Skarlatos J., Corti L., Blandamura S., Piaxxa M., et al. Hypoxia inducible factor (HIF-1α and HIF-2α) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res 61 (2001) 1830-1832
28. Talks K.L., Turley H., Gatter K.C., Maxwell P.H., Pugh C.W., Ratcliffe P.J., et al. The expression and distribution of the hypoxia inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 157 (2000) 411-421
29. Zagzag D., Zhong H., Scalzitti J.M., Laughner E., Simons J.W., and Semenza G.L. Expression of hypoxia-inducible factor 1a in brain tumors. Cancer 88 (2000) 2606-2618
30. Wenger R.H., Kvietikova I., Rolfs A., Gassmann M., and Marti H.H. Hypoxia-inducible factor-1 alpha is regulated at the post-mRNA level. Kidney Int 51 (1997) 560-563